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Curcumin is a major biological active compound from turmeric or Curcuma longa. This non-
toxic natural compound has been reported to possess several biological activities that are 
therapeutically beneficial to cancer treatment. It has been reported to increase the efficacy of 
other chemotherapeutic agents and to reduce their toxic side effects which are the major 
drawback of most chemotherapeutic agents. Curcumin is also well known for its anti- 
inflammatory activity (Amanda and Robert, 2008). Since cancer often develops under 
chronic inflammatory conditions, curcumin has the potential to be a preventive treatment 
agent against cancer. Furthermore, unlike most chemotherapeutic agents which act on a 
specific process of cancer development, i.e., cell growth or apoptosis, curcumin exerts its 
effect on various stages of cancer development, i.e., oncogene activation (Singh and Singh, 
2009), cancer cell proliferation (Simon et al., 1998), apoptosis evasion (Han et al., 1999), 
anoikis resistance (Pongrakhananon et al., 2010), and metastasis (Chen et al., 2008) (Figure 
1). Therefore, curcumin has the potential to overcome chemoresistance which is a major 
problem in cancer chemotherapy. This chapter will provide an overview of the anticancer 
activities of curcumin and present pre-clinical and clinical evidence supporting the use of 
curcumin as an anticancer agent. 
Cancer is known to be associated with genetic instability in which c-myc serves as a major 
modifier of many targeted genes (Mai and Mushinski, 2003). Likewise, the mutation of 
proto-oncogene ras has been identified in many types of tumor (Rajalingam et al., 2007). The 
dysregulation of these oncogenes is well recognized as an initial step in the development of 
tumorigenesis. Interestingly, curcumin has been reported to have a suppressive effect on the 
oncogenes and inhibit their downstream effectors such as cell cycle promoting and 
proapoptotic proteins (Singh and Singh, 2009). Curcumin also exhibits anticancer properties 
through its ability to inhibit cell proliferation and induce apoptosis. The anti-proliferative 
effect of curcumin is dependent on its concentration, duration of treatment, and specific cell 
type. At low doses, curcumin causes cell cycle arrest, while at higher doses it induces 
apoptosis. Cell proliferation is controlled by several cell cycle regulating proteins, notably 
the family of cyclin and cyclin-dependent kinases (Kastan and Bartek, 2004) whose 
expression is tightly associated with tumorigenesis (Diehl, 2002). Curcumin inhibits cell 
cycle progression by downregulating cyclin D1 and the transition from G1 to S phase in 
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human head and neck squamous carcinoma cells (Aggarwal et al., 2004). It also inhibits 
bladder cancer cell proliferation through the downregulation of cyclin A and upregulation 
of p21 (Park et al., 2006). 
 
Fig. 1. Anticancer properties of curcumin 
Curcumin possesses apoptosis-inducing activity causing cancer cell death primarily through 
the mitochondrial death pathway. It induces an upregulation of the proapoptotic protein 
Bax and downregulation of the antiapoptotic protein Bcl-2 in breast cancer cells (Chiu and 
Su, 2009), resulting in the loss of mitochondrial function, release of cytochrome c, and 
activation of caspase-9 and -3 (Chen et al., 2010). Curcumin also potentiates the cytotoxic 
effect of chemotherapeutic agents such as cisplatin (Chanvorachote et al., 2009), doxorubicin 
(Notarbartolo et al., 2005), tamoxifen (Chuang et al., 2002), and placitaxel (Genta and Amiji, 
2009). The use of curcumin as a chemo-sensitizing agent in combination therapy has the 
potential to overcome chemoresistance which is common in advance staged cancers and is a 
major cause of cancer-related death. 
An increasing number of reports have described the inhibitory effect of curcumin on cancer 
metastasis. Metastasis is a multi-step process involving tumor vascularization, cancer cell 
detachment, avoidance of anoikis, and increased cell invasion. The vascularization induced 
by tumor is an essential step providing nutrients, oxygen, and removing waste products for 
tumor growth and metastasis. A key mechanism that cancer cells utilize during metastasis is 
the acquisition of anoikis resistance. Anoikis or detachment-induced apoptosis is recognized 
as an important mechanism preventing cancer cell dissemination and invasion to form 
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secondary tumors. A recent study by our group has shown that curcumin is able to sensitize 
lung cancer cells to undergo anoikis through a mechanism that involves post-translational 
modification of Bcl-2 via the ubiquitin-proteasome pathway (Pongrakhananon et al., 2010). 
Curcumin also acts as a negative regulator of cancer cell migration and invasion through 
diverse signaling pathways including MMP-9, MMP-2 and COX-2 (Philip et al., 2004, Lee et 
al., 2005; Hong et al., 2006; Lin et al., 2009). 
Animal and clinical studies of curcumin have been well investigated. In mice, curcumin 
markedly inhibits DMBA and TPA-induced skin tumor formation (Azuine et al., 1992). In a 
xenograft model, curcumin administration significantly decreases the incidence of breast 
cancer metastasis to the lung (Aggarwal et al., 2005). In phase 1 clinical studies, oral 
administration of curcumin was shown to be well tolerated with no dose-limiting toxicity 
(Sharma et al., 2004; Lao et al., 2006). In patients with intestinal metaplasia, curcumin 
treatment showed a significant improvement in the precancerous lesion (Cheng et al., 2001), 
supporting the clinical use of curcumin as a preventive treatment agent against cancer. 
Although curcumin has demonstrated promising pharmacological effects and safety both in 
vitro and in vivo, poor bioavailability and tissue accumulation have been observed with the 
compound. Further studies on proper drug delivery, dose optimization, and biodistribution 
are needed. 
2. Chemistry of curcumin 
For thousands of years, plants and some parts of animal have been used as dietary agents 
which have been identified to be biologically active. These natural compounds have gained 
considerable interest for their potential as treatment and preventive agents for human 
diseases.  Curcumin (diferuloylmethane) is a major biologically active compound extracted 
from the dried rhizome of turmeric or Curcuma longa. It has been widely used for centuries 
as medicinal plant and food additive due to its yellow color. Its medicinal properties are 
attributed to curcuminoids, which include curcumin (curcumin I), demethoxycurcumin 
(curcumin II), and bisdemethoxycurcumin (curcumin III) (Figure 2). Curcumin I (77%) is a  
 
 
Fig. 2. Chemical structure of curcuminoids  
major component found in commercial curcumin, while curcumin II and III constitute 
approximately 17% and 3% respectively. Cucumin is a water-insoluble compound, but 
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dissolves well in ethanol, dimethylsulfoxide, and other organic solvents. The molecular weight 
of curcumin is 368.37 and melting point is 183 °C. It shows a spectrophotometric maximum 
absorption (Ȝmax) at 450 nm in methanol (Prasad and Sarasija, 1997). Fluorescence of 
curcumin occurs at 524 nm in acetonitrile and 549 nm in ethanol (Chignell et al., 1994). 
Curcumin undergoes rapid degradation in phosphate buffer and serum-free media, i.e., 90% 
within 30 minutes (Wang et al., 1997). In serum-containing (10%) media and human blood, 
curcumin is more stable with less than 20% degradation in 1 hour, and about 50% after 8 
hours. Its degradation products are trans-6-(4′-hydroxy-3′-methoxyphenyl)-2,4-dioxo-5-
hexenal (major) and vanillin, ferulic acid, and feruloyl methane (minor) (Wang et al., 1997). 
3. Anticancer properties of curcumin 
Curcumin has long been used as a dietary ingredient with known health benefits. Extensive 
research over the last decade has shown that curcumin possesses anticancer activities and 
could be used as a preventive or treatment agent against cancers, either as a single or 
combination therapy with chemotherapeutic agents. Curcumin exhibits biological activities 
in various stages of carcinogenesis including inhibition of oncogene activation, prevention 
of cancer-related inflammation, inhibition of cancer cell proliferation, induction of apoptosis 
and anoikis, prevention of metastasis, and sensitization of cancer cells to chemotherapy.  
3.1 Cancer prevention 
3.1.1 Chemopreventive properties  
Carcinogenesis is a multistep process driven by genetic instability. Continuous exposure to 
environmental and endogenous genotoxic agents can cause substantial DNA damage. The 
damaged molecules can be transmitted during cell division producing mutated clones that 
can give rise to the expansion of premalignant cell population possessing uncontrolled 
proliferative and invasive properties. Curcumin has been established as a chemopreventive 
agent that has the ability to suppress or retard the carcinogenic process induced by various 
chemical carcinogens (Table 1). In animal models of gastric and colon cancer, curcumin 
inhibits the development of cancerous and precancerous lesions induced by N-methyl-N'-
nitro-N-nitrosoguanosine (MNNG), a known mutagenic agent causing DNA methylation 
(Ikesaka et al., 2001). In the study, MNNG was given in drinking water at the concentration 
of 100 ppm for 8 weeks, and then 0.2% or 0.5% of curcumin was fed to the rats for 55 weeks. 
The results showed that the number of atypical hyperplasia in curcumin-treated rats was 
significantly less than that in the control group. Similarly, the curcumin analog bis-1,7-(2-
hydroxyphenyl)-hepta-1,6-diene-3,5-dione was shown to inhibit the tumorigenic effect of 
1,2-dimethylhydrazine in rats (Devasena et al., 2003).  Furthermore, natural and synthetic 
curcuminoids exhibit an inhibitory effect on mutagenesis induced by 2-acetamidofluorene 
(2-AAF) (Anto et al., 1996). In the study, up to 87% of 2-AAF-induced papilloma was 
inhibited by bis-(p-hydroxycinnamoyl)methane (curcuminoid III), while 70% and 68% of the 
papilloma were inhibited by feruloyl-p-hydroxycinnamoylmethane (curcuminiod II) and 
diferuloylmethane (curcuminoid I), respectively. The most potent curcuminoid was 
salicylcurcuminoid which completely inhibited the papilloma formation. 
3.1.2 Suppression of oncogenes and upregulation of tumor suppressor genes 
As mentioned earlier, genetic instability is linked to the initiation of carcinogenesis. This 
irreversible process involves several molecular events that either promote the activity of 
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oncogenes such as myc and ras or impede the function of tumor suppressor genes such as p53 
(Vogelstein and Kinzler, 2004). Curcumin has been shown to suppress oncogenes and activate 
tumor suppressor genes in various cancer cell types (Table 1). In an in vivo study, curcumin 
suppresses c-fos and c-Ha-ras activation induced by environmental mutagenic agents 
(Limtrakul et al., 2001). Dietary administration of curcumin (0.1-0.2%) prevents 2-
dimethylbenz(α)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced 
skin tumor in mice. There is an increase in the oncogene (c-fos and ras) expression in this tumor 
model, which is suppressed by the dietary curcumin. Similarly, c-myc is also a target oncogene 
attenuated by curcumin in the TPA-induced tumor model (Kakar and Roy, 1994).  
 
Chemopreventive properties 
Cancer Carcinogen Animal References 
Stomach cancer MNNG Rat Ikesaki et al., 2001 
Colon cancer DMH Rat Devasena et al., 2003 
Papilloma 2-AAF - Anto et al., 1996 
Mammary tumor DMBA Rat Pereira et al., 1996 
Skin tumor TPA Mouse Lu et al., 1993 
Liver cancer Diethylnitrosamine Mouse Chuang et al., 2000 
Oncogene suppression and tumor suppressor gene activation 
Cancer Mechanism References 
Skin tumor 
Suppress c-fos and c-Ha-ras-
activation by DMBA 
Limtrakul et al., 2001 
B cell lymphoma Suppress c-myc Han et al., 1999 
Mouse skin cancer Suppress c-myc activated by TPA Kakar & Roy, 1994 
Human colon 
adenocarcinoma 
Enhance p53 activity Song et al., 2005 
Human breast cancer Enhance p53 activity Choudhuri et al., 2002 
Human glioma Enhance p53 activity Liu et al., 2007 
Anti-inflammation -related cancer 
Cancer Mechanism References 
- Inhibit NO synthase in macrophages Brouet & Ohshima, 1995 
Human mantle cell 
lymphoma 
Inhibit constitutive NF-B activation Shishodia et al., 2005 
Mouse melanoma Inhibit constitutive NF-B activation Marin et al., 2007 
Human oral cancer Inhibit constitutive NF-B activation Sharma et al., 2006 
Non-small cell lung 
carcinoma 
Inhibit constitutive NF-B activation 
and COX expression 
Shishodia et al., 2003 
Table 1. Cancer preventive properties of curcumin 
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3.1.3 Anti-inflammatory activity  
Epidemiological studies have supported the concept that cancers frequently originate at the 
site of chronic inflammation. This event has increasingly been accepted as the seventh 
hallmark of cancer (Colotta et al., 2009). Inflammation is a vital physiological process in 
response to injury, which leads to the mediation of inflammatory cells in the presence of 
enzymes and cytokines for repairing tissue damage. The linkage between cancer and 
inflammation is generally characterized as being intrinsic or extrinsic (Mantovani et al., 
2008). The extrinsic pathway is induced by inflammation that facilitates cancer 
development, while the intrinsic pathway is driven by genetic instability causing 
inflammatory environment-related cancer. Both processes mediate the transcription factors 
involved in cell proliferative function and persistent activation of this event can lead to 
cancer. A considerable number of reports have described the linkage between cancer 
preventive properties and anti-inflammatory action of curcumin (Table 1). Mechanistically, 
curcumin inhibits the induction of nitric oxide synthase (NOS) by activated macrophages 
(Brouet and Ohshima, 1995). Nitric oxide (NO) and its derivatives such as peroxynitrite play 
a critical role in the inflammation process causing fibroblast proliferation and fibrosis 
(Romanska et al., 2002). Treatment of macrophages with lipopolysaccharide (LPS) and IFN-γ 
induces an inflammatory response that leads to the release of NO, which is inhibited by 
curcumin. Curcumin also suppresses the transcription of inducible NOS which is activated 
by LPS and IFN-γ. Since NO is implicated in tumor promotion, the attenuation of NO by 
curcumin hence suppresses tumor development.  
Numerous studies have suggested that NF-B plays a key role in promoting cancer 
development during chronic inflammation. NF-B regulates the expression of several genes 
involved in the immune and inflammatory responses as well as in cell proliferation and 
apoptosis (Karin et al., 2002). It is required for the expression of a wide range of 
inflammatory cytokines and adhesion molecules, and is important in the cellular 
proliferative function by activating growth factor genes, proto-oncogenes and cell cycle 
regulators that contribute to carcinogenesis. In a study using human mantle cell lymphoma 
(MCL), curcumin inhibits constitutive NF-B activation leading to the suppression of NF-B 
regulated genes (Shishodia et al., 2005). MCL expresses a high level of cyclin D1, a cell cycle 
promoting factor and target transcription of NF-B, which is a key survival factor of this 
cancer type. Curcumin treatment causes downregulation of constitutive NF-B activation, 
inhibits IBα kinase (IKK) and phosphorylated IBα and p65, leading to cell cycle arrest and 
apoptosis. NF-B is overexpressed in various tumors and cancer cell lines including 
melanoma cells. Electrophoretic mobility shift and gene reporter assays have demonstrated 
that curcumin suppresses constitutive NF-B activation in melanoma cells and increases the 
number of cells in the sub G1 phase of cell cycle (Marin et al., 2007). Interestingly, curcumin 
shows selectivity in inducing apoptosis of melanoma cells but not melanocytes.  
Other mechanisms of the anti-inflammatory-related cancer effect of curcumin have been 
proposed including suppression of cyclooxygenase 2 (COX-2). A wide range of stimuli 
mediates COX-2 expression and overexpression of this molecule is found in various cancer 
types in association with accelerated cell growth, antiapoptotic activity, angiogenesis, and 
metastasis (Prescott and Fitzpatrick, 2000). In a cigarette-smoking (CS) study using non-
small cell lung cancer model, CS exposure activates NF-B and subsequently induces COX-2 
expression, which is inhibited by pre-treatment with curcumin (Shishodia et al., 2003). This 
chemopreventive property of curcumin is also observed in smokeless-tobacco mediated 
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activation of NF-B and its downstream target COX-2 (Sharma et al., 2006). Since 
inflammation contributes to tumor initiation, and curcumin possesses anti-inflammatory 
activity, curcumin could be beneficial in cancer prevention.  
3.2 Inhibition of tumor growth and cell proliferation  
Excessive proliferation is a hallmark of cancer (Hanahan and Weinberg, 2000). Aberrational 
cell division is an important basis of cancer development allowing formation and expansion 
of tumor growth. In normal cells, cell proliferation requires the growth signal that is 
generated by cell-cell interaction, neighbour cells and extracellular matrix. Cancer cells can 
further generate their own growth signals, upregulate growth receptors, and be desensitized 
to antigrowth factors. Upon transmitting the growth signals to their receptors, downstream 
mediators are activated which drive the quiescent cells to proliferative cycle (Evan and 
Vousden, 2001). Curcumin has been shown to modulate the expression and activity of 
growth factors, including epidermal growth factor (EGF) and insulin-like growth factor 
(IGF) (Table 2). Overexpression of EGF and its receptor, EGFR, was found in human 
prostate cancer cells undergoing rapid growth expansion (Cai et al., 2008). It has been 
demonstrated that curcumin blocks the EGF pathway through downregulation of EGFR, 
suppression of intrinsic EGFR tyrosine kinase activity, and inhibition of ligand-induced 
EGFR activity in both androgen-dependent and androgen-independent prostate cancer cells 
(Dorai et al., 2000).  
 
Inhibition of  cancer proliferation and tumor growth 
Cancer Mechanism References 
Prostate cancer cells Downregulation of EGFR, 
suppression of intrinsic EGFR 
tyrosine kinase activity, and 
inhibition ligand-induced EGFR 
activity 
Dorai et al., 2000 
Prostate and breast cancer 
cells 
Downregulation of cyclin D1  Mukhopadhyay et al., 
2002 
Breast cancer cells Suppression IGF system Xia et al., 2007 
Breast cancer cells Induction of cell cycle arrest at S, 
G2/M phase by upregulation of p21 
Chiu & Su, 2009 
Human epidermoid 
carcinoma cells 
Inhibit EGFR activity Korutla & Kumar, 1994 
Colon carcinoma cells Induction of cell cycle arrest at S, 
G2/M phase  
Chen et al., 1999 
Human head and neck 
squamous carcinoma cells 
Downregulation of cyclin D1 Aggarwal et al., 2004 
Human biliary cancer cells Downregulation of cyclin D1 Prakobwong et al., 2011 
Human hepatocarcinoma 
cells 
Induction of cell cycle arrest at S, 
G2/M phase 
Cheng et al., 2010 
Table 2. Inhibition of  cancer proliferation and tumor growth 
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Likewise, insulin-like growth factor has been implicated in the regulation of normal cell 
growth, in which its atypical expression is found in human cancer cells (Samani et al., 2007). 
Curcumin abrogates IGF-1 system in MCF-7 human breast carcinoma cells (Xia et al., 2007). 
It decreases IGF-1 secretion in concomitant with the increasing IGF binding protein IGFBP-3 
in a dose-dependent fashion. Furthermore, it abolishes IGF-1-stimulated MCF-7 growth 
through the suppression of IGF-1 mediated receptor activity and downregulation of IGF 
receptor mRNA expression.  
Deregulation of cell cycle causes limitless replicative potential of cancer. Curcumin exhibits 
antiproliferative activity via the regulation of cell cycle (Table 2). It disrupts the progression 
of cell cycle by increasing the number of cancer cells at S, G2/M phase, hence preventing 
cell entering next cycle (Chen et al., 1999). Additional mechanistic studies indicate that 
curcumin downregulates cyclin D1 expression through inhibition of its promoter activity 
and enhanced degradation (Mukhopadhyay et al., 2002). Cyclin D1 is a subunit of cyclin-
dependent kinase (Cdk)-4 and Cdk-6 which plays a key role in determining the cell cycle 
progression from G1 to S phase (Baldin et al., 1993) and overexpression of this gene is a 
common event in several forms of cancer (Knudsen et al., 2006). Similarly, in the presence of 
curcumin, cyclin D1 is suppressed as a result of NF-B inhibition as observed in human 
head carcinoma, neck squamous carcinoma, and biliary cancer cells (Aggarwal et al., 2004; 
Prakobwong et al., 2011). 
3.3 Induction of cancer cell apoptosis 
Apoptosis plays an essential role in various physiological and pathological processes 
(Hengartner, 2000). Tissue homeostasis maintains the balance of cell proliferation and cell 
death as part of normal tissue development. Dysregulation of this process can lead to 
several diseases including cancer. Avoidance of apoptotic cell death is a major characteristic 
of malignant cells in response to stress conditions, which is achieved by activating the 
antiapoptotic signals or inhibiting proapoptotic signals (Hanahan and Weinberg, 2000). 
Several strategies have been developed to overcome this defective mechanism in cancers 
and curcumin has shown promising activities that modulate this mechanism in favor of 
cancer cell apoptosis.  
Apoptosis generally occurs through two main pathways, intrinsic and extrinsic (Lavrik et 
al., 2005). The intrinsic pathway is initiated by several cellular stresses such as DNA damage 
which activates proapoptotic proteins, notably the Bcl-2 family proteins, causing 
mitochondrial membrane permeabilization and subsequent activation of the caspase 
cascade. In the extrinsic pathway, the interaction between death ligands and death receptors 
results in the assembly of death-inducing signaling complex (DISC) and the activation of 
initiator caspases. Curcumin is known to overcome the apoptosis resistance of cancer cells 
through both pathways (Table 3). In human acute myelogenous leukemia HL-60 cells, 
curcumin induces apoptosis by suppressing the expression of antiapoptotic Bcl-2 and Bcl-
xL, causing cytochrome c release, caspase-3 activation, and PARP cleavage (Anto et al., 
2002). Curcumin also stimulates the death receptor pathway through caspase-8 activation 
but overexpression of the DISC protein FADD cannot protect the cells from apoptosis in 
response to curcumin. In A549 lung adenocarcinoma cells, curcumin treatment up-regulates 
the mitochondrial Bax protein expression, suggesting the intrinsic pathway as a major 
pathway of curcumin-induced apoptosis in this cell type (Chen et al., 2010).  
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Molecular mechanisms of curcumin-induced apoptosis 
Cancer Mechanism References 
Human acute myelogenous 
leukemia cells 
Downregulation of Bcl-2 and Bcl-
xL 
Anto et al., 2002 
Lung adenocarcinoma cells Upregulation of Bax and 
Downregulation of Bcl-2  
Chen et al., 2010 
Rat histocytoma cells Induction of ROS production Bhaumik et al., 1999 
Human gingival fibroblasts 
and human submandibular 
gland carcinoma cells 
Induction of ROS production Atsumi et al., 2006 
Human breast cancer cells Downregulation of anti-apoptotic 
and upregulation of proapoptotic 
proteins in a p53-dependent 
manner 
Choudhuri et al., 2002 
Human breast cancer cells  Inhibition of PI3K/Akt pathway  Squires et al., 2003 
Human breast and hepatic 
cancers cells 
Glutathione depletion and ROS 
production 
Syng-Ai et al., 2004 
Human ovarian cancer cells Upregulation of caspase-3 and 
downregulation of NF-B  
expression 
Zheng et al., 2002 
Human colon cancer cells Induction of ROS production and 
deactivation of JNK pathway 
Moussavi et al., 2006 
Human colon 
adenocarcinoma cells 
Downregulation of anti-apoptotic 
and upregulation of proapoptotic 
proteins in a p53-dependent 
manner 
Song et al., 2005 
Human melanoma cells Activation of caspase-3, and -8, 
Fas receptor aggregation, 
suppression of NF-B activation, 
and downregulation of XIAP 
expression 
Bush et al., 2001 
T cell leukemia cells Inhibition of PI3K/Akt pathway  Hussain et al., 2006 
Prostate cancer cells Inhibition of PI3K/Akt pathway  Shankar & Srivastava, 
2007 
Human glioblastoma cells Increasing Bax:Bcl-2 ratio, 
activation of caspase-8, -9, and -3, 
downregulation of NF-B 
Karmakar et al., 2006 
Breast cancer cells Inhibition of MAPK and 
PI3K/Akt pathway 
Squires et al., 2003 
Table 3. Molecular mechanisms of curcumin-induced apoptosis 
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In human melanoma cells, curcumin induces apoptosis through the extrinsic pathway by 
activating caspase-8 (Bush et al, 2001). Inhibition of caspase-8 by specific caspase-8 inhibitor 
or pan-caspase inhibitor prevents cancer cell apoptosis, whereas specific caspase-9 inhibitor 
lacks this ability. The underlying apoptosis mechanism involves the induction of Fas 
receptor oligomerization independent of Fas ligand, supporting the role of death receptor 
modification in curcumin-induced apoptosis. In some cancers such as human glioblastoma 
T98G cells, curcumin induces apoptosis through both pathways (Karmakar et al., 2006). 
The activation of apoptotic pathwas by curcumin is regulated by reactive oxygen species 
(ROS). In various cancer cell types including H460 non-small cell lung cancer cells 
(Chanvorachote et al., 2009), AK5 rat histocytoma cells (Bhaumik et al., 1999), human 
gingival fibroblasts (HGF), and human submandibular gland carcinoma (HSG) cells (Atsumi 
et al., 2006), the induction of apoptosis by curcumin requires ROS generation. Likewise, in 
MCF-7, MDAMB, and HepG2 cells, apoptosis is mediated through oxidative stress induced 
by curcumin as a result of glutathione depletion (Syng-Ai et al., 2004). In colon cancer cells, 
curcumin-induced cell death is associated with ROS generation that converges on JNK 
activation (Moussavi et al., 2006). 
Other mechanisms of curcumin-induced apoptosis have been reported. In human HT-29 
colon adenocarcinoma (Song et al., 2005) and breast cancer cells (Choudhuri et al., 2002), 
curcumin upregulates proapoptotic proteins and downregulates antiapoptotic proteins in 
the Bcl-2 family through p53-dependent mechanism. In T cell leukemia (Hussain et al., 2006) 
and breast cancer cells (Squires et al., 2003), apoptosis induced by curcumin involves 
PI3K/Akt signaling pathway. Curcumin inhibits Akt phosphorylation and upregulates p53 
expression which induces the proapoptotic Bcl-2 family proteins facilitating cell apoptosis 
(Shankar and Srivastava, 2007).  
3.4 Sensitization of cancer cells to chemotherapy 
In addition to its direct apoptosis-inducing effect, curcumin has been reported to sensitize 
cancer cells to chemotherapy-induced cell death. The main problem of cancer chemotherapy 
is the acquisition of apoptosis resistance of cancer cells and the cytotoxicity to normal cells. 
Combination therapy is an alternative approach that can overcome this problem by 
potentiating the effects of combination drugs and reducing their cytotoxicity by using 
optimal dosage regimens. Curcumin is one such agent that has been investigated for its 
effect in combination therapy (Table 4). In non-small cell lung cancer cells, we have recently 
shown that cotreatment of the cells with cisplatin and curcumin results in a substantial 
increase in cancer cell death as compared to cisplatin treatment alone (Chanvorachote et al., 
2009). Since cisplatin-based therapy is the first line drug for treatment of lung cancer and the 
efficacy of this drug is frequently attenuated by the development of drug resistance 
especially in advanced stage cancer (Chang, 2011), curcumin has the potential to overcome 
this resistance problem. Curcumin promotes the apoptotic effect of cisplatin by inducing 
superoxide anion and downregulating the anti-apoptotic Bcl-2 protein which facilitates the 
cancer cell killing by cisplatin. 
In pancreatic cancer cells, the acquisition of apoptosis resistance to the combination therapy 
of gemcitabine and capecitabine (a prodrug of 5-fluorouracil, 5-FU) is frequently observed. 
It is thought that overexpression of the multidrug resistance-associated protein 5 (MRP5), 
which promotes cellular efflux of the drugs (Szakacs et al., 2006), contributes to the 
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resistance. Curcumin was shown in a recent study to inhibit MRP5 activity and increase the 
sensitivity of pancreatic cancer cells to 5-FU-induced toxicity in a dose-dependent manner 
(Li et al., 2010). 
 
Cancer cells Chemotherapeutic drugs References 
Non-small cell lung cancer cells Cisplatin Chanvorachote et al., 2009 
Pancreatic cancer cells 5-Fluorouracil Li et al., 2010 
Hela cells Taxol Bava et al., 2005 
Human hepatic cancer cells Doxorubicin Notarbartolo et al., 2005 
Hepatocellular carcinoima cells  Doxorubicin Chuang et al., 2002 
Human ovarian adenocarcinoma 
cells 
Paclitaxel Ganta & Amiji, 2009 
Human melanoma cells Tamoxifen Chatterjee & Pandey, 2011 
Human colorectal cancer cells Oxaliplatin Howells et al., 2010 
Bladder cancer cells Gemcitabine Tharakan et al., 2010 
Table 4. Curcumin potentiates chemotherapeutic agent-induced cancer cell death 
Curcumin also augments the therapeutic effect of taxol in Hela cells (Bava et al., 2005). The 
synergistic mechanism involves the inhibition of NF-B activation and Akt phosphorylation 
which results in increased apoptosis and decreased DNA synthesis of cancer cells 
independent of tubulin polymerization. The increased susceptibility of cancer cells to 
chemotherapeutic agents by curcumin might overcome the drug resistance problem, thus 
improving the clinical outcomes. 
3.5 Inhibition of cancer metastasis 
Cancer metastasis is the spread of cancer cells from the initiation site to other parts of the 
body, and particularly presented in several advanced stage cancers which are difficult to 
treat (Gubta and Massagué, 2006). Cancer metastasis is a multistep process involving 
complex interactions between the disseminating cancer cells and their microenvironment. 
When transformed cells are initiated and continue to grow at the primary site, angiogenic 
factors are synthesized for vascularization which increases the likelihood of tumor cells to 
enter in the blood stream or lymphatic system and colonize at distant sites. Once at the new 
sites, the extravasation of cancer cells allows the formation and growth of secondary tumors 
which complete the metastatic process (Fidler, 2003). Agents that inhibit metastasis provide 
a major advantage in treating cancers. Several studies have shown that curcumin inhibits 
cancer angiogenesis, migration and invasion by interacting with key regulatory molecules  
as summarized in Table 5. 
It is well established that vascular endothelial growth factor (VEGF) and matrix metallo-
proteinase family proteins (MMP) are essential factors in the angiogenesis and invasion of 
cancer cells (Carmeliet, 2005; Helmestin et al., 1994). In non-small cell lung cancer cells, 
VEGF, MMP-9 and MMP-2 are inhibited by curcumin through MEKK and ERK-dependent 
pathways, resulting in inhibition of cell migration and invasion (Lin et al., 2009). Similarly, 
in a human glioblastoma xenograft mouse model, curcumin inhibits tumor growth, 
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suppresses angiogenesis, and increases animal survival through the inhibition of MMP-9 
and neovascularization (Perry et al., 2010).  Curcumin also acts as a potent inhibitor of breast 
cancer cell motility and invasion through the attenuation of MMP-3 which acts as an 
invasive factor in this cancer cell type (Boonrao et al., 2010).  
 
Cancer Effects Mechanism References 
Human non-small 
cell lung cancer 
Inhibition of cell 
invasion and 
migration 
Inhibition of VEGF, MMP-9, 
and MMP-2 through MEKK 
and ERK pathway 









cancer motlity and 
invasion 
Attenuation of MMP-3 
activity 
Boonrao et al., 2010 
Human non-small 
cell lung cancer 
Sensitization of 
cancer cell anoikis 









Activation of tumor 
suppressor HLJ1 through 
JNK/JunD pathway  






mediated activator protein-1 
and NF-B activation, and 
suppression of neurotensin-
stimulated IL-8 gene 
induction 
Wang et al., 2006 
Prostate cancer Inhibition of 
invasion 
Downregulation of MMP-2 
and MMP-9 






Downregulation of MMP-2, 
MMP-9, uPA, MT1-MMP, and 
TIMP-2 
Yodkeeree et al., 
2008 
Table 5. Antimetastatic properties of curcumin 
Several studies have investigated the molecular mechanisms of cancer cell survival during 
metastasis. Survival of primary cancer cells in the circulation is a key factor determining its 
metastatic ability. In general, most adherent cells undergo apoptosis when detached due to 
improper environmental conditions. This detachment-induced apoptosis or anoikis which is 
often impaired in metastatic cancers (Mehlen and Puisieux, 2006) has increasingly been 
recognized as an important mechanism for controlling cancer cell dissemination and 
invasion to secondary sites. A recent study by our group has shown that curcumin can 
sensitize non-small cell lung cancer cells to anoikis (Pongrakhananon et al., 2010) through a 
mechanism that involves Bcl-2 downregulation through ubiquitin-proteasomal degradation. 
This process is dependent on ROS generation, partcularly superoxide anion which mediates 
the Bcl-2 degradation process, consistent with the previous findings on the pro-oxidant 
properties of curcumin  (Bhaumik et al., 1999; Khar et al., 2001; Wang et al., 2008). 
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3.6 Animal studies 
Several animal studies have been reported on the anticancer and chemopreventive effects of 
curcumin in various cancer types. Since the in vivo chemopreventive effect of curcumin has 
earlier been described under 3.1.1 and summarized in Table 1, we will focus on the direct in 
vivo anticancer properties of curcumin.  
The anticancer property of curcumin in prostate cancer was investigated by using prostate 
cancer cells implanted into nude mice (Dorai et al., 2001). Dietary curcumin at the 
concentration of 2% was given to the mice, and after 6 weeks of treatment the animals were 
examined for tumor growth, apoptosis, and vascularity. The results showed that curcumin 
was able to decrease tumor volume, increase cancer cell apoptosis, and inhibit vascular 
angiogenesis as indicated by the reduction in microvessel density. A similar study using a 
murine xenograft model of human lung carcinoma cells was reported (Su et al., 2010). In this 
study, NCI-H460 cells were implanted subcutaneously into nude mice, and curcumin (30 
and 45 mg/kg of bodyweight) was intraperitoneally injected into the mice every 4 days after 
the tumor reached 100 mm3 in size. Curcumin was shown to significantly decrease the 
tumor size as compared to non-treated control. 
The antitumor property of curcumin-encapsulated nanoparticles was investigated in the 
xenograft mouse model of human pancreatic cancer (Bisht et al., 2010). The nanoparticle 
formulation was injected twice daily for 3 weeks into the xenografted mice. Plasma 
concentration of curcumin was sustained in the treated mice at Tmax of 2.75 ± 1.50 h and 
Cmax of 17,176 ± 5,176 ng/ml. Tumor volume was substantially decreased in curcumin 
treated group. A greater antitumor effect was observed when curcumin was combined with 
gemcitabine. Curcumin also exhibited antimetastatic activity which was greatly enhanced 
by the combination treatment. The underlying mechanism of curcumin action involves NF-
B activation and downregualtion of cyclin D1 and MMP-9. 
Curcumin also improves the therapeutic activity of paclitaxel in breast cancer (Aggarwal et 
al., 2005). Since most metastatic breast cancers acquire apoptosis resistance to paclitaxel, 
which is the first line therapy for breast cancer, a combination therapy with apoptosis-
sensitizing agents such as curcumin could be beneficial. In a mouse model of breast cancer 
metastasis, curcumin was shown to decrease the incidence of breast cancer metastasis to the 
lung as compared to paclitaxel treatment alone. Tissue sections from treated animals 
showed that NF-B, MMP-9, and COX-2 expression were increased in the paclitaxel-treated 
group but suppressed in the curcumin co-treatment group, supporting the ability of 
curcumin to abrogate paclitaxel resistance in this metastatic breast cancer model. 
3.7 Clinical studies 
Several clinical studies are ongoing to investigate the efficacy and safety of curcumin as a 
preventive treatment agent for a variety of cancers. In prospective phase I clinical trials, 
curcumin was shown to be safe even at high doses (Cheng et al., 2001). In this study, 
patients with premalignant lesions caused by oral leukoplakia, intestinal metaplasia, uterine 
cervical intraepithelial neoplasia, skin Bowen’s disease, and bladder cancer were given a 
curcumin tablet which was taken orally for the period of three months at the daily dose of 
500, 1000, 2000, 4000, and 8000 mg. No toxicity was observed in these patients even the 
highest dose (8000 mg/day). However, this dose was unacceptable by the patients due to its 
bulky volume. Peak serum concentration of curcumin after the 4000 mg administration was 
0.51±0.11 ȝM, and 0.63±0.06 ȝM and 1.77±1.87 ȝM respectively after the 6000 mg and 8000 
mg dosing. A similar study showed that a single dose of curcumin up to 12,000 mg had no 
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dose-limiting toxic effect in healthy volunteers, not even minor adverse effects such as 
diarrhea (Lao et al., 2006).  
Expanding from the above findings, another phase I clinical study was conducted in 
patients with colon adenocarcinoma to investigate the phamacodynamic of curcumin 
(Sharma et al., 2004). Curcuminoid, formulated as 500 mg in soft gelatin capsule containing 
450 mg of curcumin, 40 mg of desmethoxycurcumin, and 10 mg of bisdesmethoxycurcumin, 
was taken orally at the dose of 450, 900, 1800, and 3600 mg/day of curcumin for 4 months. 
Since curcumin is known to induce glutathione S-transferase (GST), suppress prostaglandin 
E2 (PGE2) production, and inhibit oxidative DNA adduct (M1G) formation, these 
biomarkers are frequently used to indicate curcumin efficacy. Curcumin and its metabolites 
were collected from plasma, urine, and feces, and analyzed to assess the pharmacokinetic 
parameters. The results showed that curcumin was well tolerated by the patients without a 
dose-limiting toxicity, except in a few cases where patients reported a minor gastrointestinal 
upset. The result also showed that curcumin at the dose of 3600 mg/day was suitable for 
phase II evaluation. Curcumin was shown to inhibit PGE2 without affecting GST and M1G, 
suggesting that GST and M1G may not be useful as indicators for curcumin efficacy. 
Furthermore, curcumin and its glucuronide and sulfate metabolites were found in the 
plasma and urine. The presence of these metabolites at all time points indicates that 
curcumin has poor systemic availability when given orally.  
Consistent with the above finding, numerous other studies have demonstrated low systemic 
bioavailability of curcumin resulting from poor absorption, rapid metabolism, and rapid 
systemic elimination (Hsu et al., 2007; Ireson et al., 2001; Maiti et al., 2007; Garcea et al., 
2004). Glucuronide and sulfate metabolites of curcumin are rapidly detected in the 
peripheral and portal circulation after curcumin administration (Garcea et al., 2004). In this 
study, patients with liver metastasis from colorectal adenocarcinoma were administered 
orally with curcumin at the daily dose of 450, 1800, and 3600 mg for a week. No curcumin or 
its metabolites was detected in the bile or hepatic tissue, indicating that curcumin is not 
suitable for treating patients with tumors distant from the absorption site. 
In a phase II clinical study conducted in patients with advanced pancreatic cancer, curcumin 
was administered orally at the dose of 8 g/day for 8 weeks (Dhillon et al., 2008). The 
treatment was well tolerated by the patients with no systemic side effects, while effectively 
reducing the tumor size and the activation of NF-B and COX-2. Mechanistically, curcumin 
induces cancer cell apoptosis through an upregulation of p53 in the tumor tissues (He et al., 
2011). 
4. Conclusion 
Curcumin has a great potential in cancer therapy and is gaining wide acceptance as a 
preventive treatment agent due to its safety. It affects multiple steps in the carcinogenic 
process, which is important in avoiding chemoresistance. Clinical studies have indicated its 
efficacy as a single agent or in combination therapy; however, more rigorous testing are 
needed. Furthermore, problems associated with the low bioavailability of curcumin, 
including poor absorption, rapid metabolism, and limited tissue distribution, must be 
addressed. Current strategies that have been investigated to overcome these problems 
include alternative administration routes, chemical modifications, and various drug delivery 
and formulation strategies. These strategies will likely benefit the development of curcumin 
as an anticancer agent.  
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